Lowe Brockenbrough & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $859K | Sell |
6,162
-4
| -0.1% | -$560 | 0.04% | 187 |
|
|
2025
Q4 | $757K | Sell |
6,166
-340
| -5% | -$41.3K | 0.04% | 192 |
|
|
2025
Q3 | $722K | Hold |
6,506
| – | – | 0.04% | 195 |
|
|
2025
Q2 | $721K | Sell |
6,506
-511
| -7% | -$54.4K | 0.04% | 195 |
|
|
2025
Q1 | $786K | Sell |
7,017
-716
| -9% | -$73.9K | 0.05% | 188 |
|
|
2024
Q4 | $714K | Sell |
7,733
-35
| -0.5% | -$3.15K | 0.05% | 196 |
|
|
2024
Q3 | $651K | Buy |
7,768
+858
| +12% | +$65.5K | 0.04% | 206 |
|
|
2024
Q2 | $474K | Sell |
6,910
-500
| -7% | -$33.4K | 0.03% | 219 |
|
|
2024
Q1 | $543K | Sell |
7,410
-2,006
| -21% | -$154K | 0.04% | 213 |
|
|
2023
Q4 | $763K | Buy |
9,416
+1,968
| +26% | +$153K | 0.06% | 190 |
|
|
2023
Q3 | $558K | Sell |
7,448
-3,000
| -29% | -$231K | 0.04% | 205 |
|
|
2023
Q2 | $805K | Hold |
10,448
| – | – | 0.06% | 193 |
|
|
2023
Q1 | $867K | Buy |
10,448
+38
| +0.4% | +$3.15K | 0.07% | 184 |
|
|
2022
Q4 | $894K | Buy |
10,410
+500
| +5% | +$39.6K | 0.08% | 180 |
|
|
2022
Q3 | $611K | Hold |
9,910
| – | – | 0.06% | 194 |
|
|
2022
Q2 | $613K | Sell |
9,910
-169
| -2% | -$10.5K | 0.05% | 196 |
|
|
2022
Q1 | $599K | Sell |
10,079
-385
| -4% | -$24.6K | 0.04% | 206 |
|
|
2021
Q4 | $760K | Hold |
10,464
| – | – | 0.06% | 188 |
|
|
2021
Q3 | $731K | Sell |
10,464
-1,000
| -9% | -$70.3K | 0.06% | 196 |
|
|
2021
Q2 | $789K | Hold |
11,464
| – | – | 0.07% | 163 |
|
|
2021
Q1 | $741K | Buy |
11,464
+29
| +0.3% | +$1.87K | 0.07% | 163 |
|
|
2020
Q4 | $666K | Sell |
11,435
-75
| -0.7% | -$4.53K | 0.07% | 159 |
|
|
2020
Q3 | $727K | Sell |
11,510
-45
| -0.4% | -$3.12K | 0.09% | 153 |
|
|
2020
Q2 | $889K | Sell |
11,555
-385
| -3% | -$29.5K | 0.12% | 145 |
|
|
2020
Q1 | $893K | Sell |
11,940
-69,752
| -85% | -$4.82M | 0.15% | 132 |
|
|
2019
Q4 | $5.31M | Buy |
81,692
+2,375
| +3% | +$155K | 0.66% | 54 |
|
|
2019
Q3 | $5.03M | Buy |
79,317
+2,397
| +3% | +$157K | 0.67% | 52 |
|
|
2019
Q2 | $5.2M | Buy |
76,920
+210
| +0.3% | +$13.8K | 0.71% | 49 |
|
|
2019
Q1 | $4.99M | Buy |
76,710
+17
| +0% | +$1.13K | 0.7% | 51 |
|
|
2018
Q4 | $4.8M | Sell |
76,693
-14,505
| -16% | -$1.01M | 0.78% | 45 |
|
|
2018
Q3 | $7.04M | Buy |
91,198
+175
| +0.2% | +$13.2K | 0.98% | 35 |
|
|
2018
Q2 | $6.45M | Buy |
91,023
+240
| +0.3% | +$16.9K | 0.95% | 36 |
|
|
2018
Q1 | $6.84M | Buy |
90,783
+355
| +0.4% | +$28.2K | 1.01% | 32 |
|
|
2017
Q4 | $6.48M | Buy |
90,428
+71,233
| +371% | +$5.41M | 0.93% | 37 |
|
|
2017
Q3 | $1.55M | Sell |
19,195
-200
| -1% | -$15.3K | 0.24% | 104 |
|
|
2017
Q2 | $1.37M | Sell |
19,395
-60
| -0.3% | -$3.99K | 0.22% | 105 |
|
|
2017
Q1 | $1.32M | Buy |
19,455
+60
| +0.3% | +$4.22K | 0.21% | 106 |
|
|
2016
Q4 | $1.39M | Sell |
19,395
-550
| -3% | -$40.9K | 0.23% | 101 |
|
|
2016
Q3 | $1.58M | Buy |
19,945
+500
| +3% | +$40.6K | 0.27% | 89 |
|
|
2016
Q2 | $1.62M | Sell |
19,445
-425
| -2% | -$37.7K | 0.28% | 88 |
|
|
2016
Q1 | $1.82M | Sell |
19,870
-2,000
| -9% | -$180K | 0.31% | 85 |
|
|
2015
Q4 | $2.21M | Hold |
21,870
| – | – | 0.38% | 80 |
|
|
2015
Q3 | $2.15M | Hold |
21,870
| – | – | 0.38% | 85 |
|
|
2015
Q2 | $2.56M | Sell |
21,870
-1,250
| -5% | -$137K | 0.41% | 80 |
|
|
2015
Q1 | $2.27M | Sell |
23,120
-2,381
| -9% | -$242K | 0.36% | 83 |
|
|
2014
Q4 | $2.4M | Sell |
25,501
-9,225
| -27% | -$954K | 0.38% | 80 |
|
|
2014
Q3 | $3.7M | Sell |
34,726
-1,105
| -3% | -$108K | 0.59% | 62 |
|
|
2014
Q2 | $2.97M | Hold |
35,831
| – | – | 0.47% | 72 |
|
|
2014
Q1 | $2.54M | Sell |
35,831
-725
| -2% | -$56.9K | 0.42% | 77 |
|
|
2013
Q4 | $2.75M | Sell |
36,556
-800
| -2% | -$55.7K | 0.45% | 72 |
|
|
2013
Q3 | $2.35M | Sell |
37,356
-550
| -1% | -$32.9K | 0.43% | 75 |
|
|
2013
Q2 | $1.94M | Buy |
+37,906
| New | +$1.98M | 0.36% | 81 |
|
Other funds holding GILD
VCM
VPM
Lowe Brockenbrough & Co's GILD Position: Q1 2026 in Review
Lowe Brockenbrough & Co reduced its Gilead Sciences (GILD) stake by 0.06% in Q1 2026, selling an estimated $560 and leaving 6,162 shares worth $859K. The position accounts for 0.04% of the portfolio, ranked #187.
Lowe Brockenbrough & Co first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.04M in Q3 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Lowe Brockenbrough & Co held 6,162 shares of Gilead Sciences worth $859K as of Q1 2026.
- Lowe Brockenbrough & Co sold 4 Gilead Sciences shares in Q1 2026, an estimated $560.
- Gilead Sciences made up 0.04% of Lowe Brockenbrough & Co's portfolio in Q1 2026, its #187 holding.
- Lowe Brockenbrough & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
- Lowe Brockenbrough & Co's Gilead Sciences position peaked at $7.04M in Q3 2018.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Lowe Brockenbrough & Co's 13F filing for Q1 2026, filed 7 May 2026.